BioMotiv

Founded in 2017, Amphista Therapeutics is a biopharmaceutical company based in Motherwell, UK. It specializes in developing first-in-class cancer therapeutics using targeted protein degradation technology to selectively remove disease-causing proteins.

Aro Biotherapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing a novel protein drug platform known as Centyrins. These small, non-antibody protein scaffolds are designed to enhance treatment efficacy and safety for patients with cancer and other serious diseases. Aro Biotherapeutics has established a wholly-owned pipeline of Centyrins targeted at oncology and immunology applications. The unique structure of Centyrins allows for multi-specificity and the targeted delivery of complex drug payloads, including nucleic acids, which may aid in advancing therapeutic mechanisms and unlocking the potential of genetic medicines. Established in 2017, the company aims to innovate treatments that improve patient outcomes in challenging medical conditions.

Founded in 2017, Amphista Therapeutics is a biopharmaceutical company based in Motherwell, UK. It specializes in developing first-in-class cancer therapeutics using targeted protein degradation technology to selectively remove disease-causing proteins.

Aro Biotherapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing a novel protein drug platform known as Centyrins. These small, non-antibody protein scaffolds are designed to enhance treatment efficacy and safety for patients with cancer and other serious diseases. Aro Biotherapeutics has established a wholly-owned pipeline of Centyrins targeted at oncology and immunology applications. The unique structure of Centyrins allows for multi-specificity and the targeted delivery of complex drug payloads, including nucleic acids, which may aid in advancing therapeutic mechanisms and unlocking the potential of genetic medicines. Established in 2017, the company aims to innovate treatments that improve patient outcomes in challenging medical conditions.

Allinaire Therapeutics is a biotechnology company focused on developing novel therapeutics for chronic obstructive pulmonary disease (COPD) and other pulmonary diseases, including cardiopulmonary conditions such as pulmonary arterial hypertension. Incorporated in 2015 and based in Cleveland, Ohio, the company builds on a therapeutic target identified by founders Irina Petrache, MD, and Matthias Clauss, Ph.D., which plays a central role in lung disease development and progression. The goal is to translate this target into treatments that could slow or halt disease progression and improve outcomes for patients with PAH and related conditions.

Orca Pharmaceuticals Ltd. is a biotechnology company based in Abingdon, United Kingdom, founded in 2012. The company specializes in developing oral medications aimed at treating chronic inflammatory and autoimmune diseases, including psoriasis, ankylosing spondylitis, and inflammatory bowel disease. Orca Pharmaceuticals focuses on addressing imbalances between pathogenic T cells and regulatory T cells by targeting pathogenic Th17 cells and innate lymphoid cells. This innovative approach seeks to enhance treatment efficacy for patients suffering from these conditions, leveraging technology developed in collaboration with New York University.